This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Androgen resistance syndrome / Androgen insensitivity syndrome, AIS안드로젠저항증후군 (안드로젠 불감성 증후군)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: E34.5 (Androgen resistance syndrome) | OMIM: 300068 (CAIS), 312300 (PAIS) | Gene: AR (Xq11-12) | Special Copayment Reduction: V166 (rare disease)
B. SynonymsAndrogen insensitivity syndrome (AIS), complete androgen insensitivity syndrome (CAIS), partial androgen insensitivity syndrome (PAIS), mild androgen insensitivity syndrome (MAIS), testicular feminization syndrome (outdated term)
C. Adult onsetCAIS presents with primary amenorrhea at puberty or inguinal hernia; PAIS/MAIS diagnosed from childhood to adulthood with undervirilization or infertility. Many cases first diagnosed in adulthood.
1. History1953 Morris describes testicular feminization syndrome → 1976 absence of androgen receptor identified → 1988 cloning of the AR gene → molecular classification established.
2. CausesVariants in the AR gene (Xq11-12) cause loss or reduction of androgen receptor function → impaired androgen action in target tissues.
3. GeneticsX-linked recessive. More than 1,000 pathogenic variants reported throughout AR gene exons 1–8. De novo mutations about 30%. Nuclear receptor superfamily; variants in the DNA-binding domain and ligand-binding domain determine clinical severity.
4. General epidemiologyCAIS incidence about 1/20,000–1/64,000 XY births. Sex discordance (46,XY karyotype, female phenotype). Few registered cases in Korea, but the actual number is presumed to be higher.
5. PathophysiologyLoss of AR function → failure of virilization of the external genitalia in fetal life → formation of female external genitalia. Anti-Müllerian hormone (AMH) normal → absence of uterus and fallopian tubes. Lack of androgen action from fetal life through puberty.
6. SymptomsCAIS: female phenotype, primary amenorrhea, testes within an inguinal hernia. PAIS: various intermediate phenotypes (hypospadias, clitoromegaly, etc.). MAIS: male, gynecomastia, infertility.
7. SignsCAIS: female external genitalia, absent uterus, blind-ending vagina, sparse body and pubic hair, testes (intra-abdominal or inguinal). Elevated LH, testosterone, and estradiol. 46,XY karyotype.
8. ScreeningKaryotyping in primary amenorrhea or inguinal hernia (in girls). Hormone profile and AR gene testing in newborns with differences of sex development (DSD). Screening of XY newborns with a family history.
9. DiagnosisKaryotype analysis (46,XY). Hormones (LH, FSH, testosterone, AMH, estradiol). Pelvic ultrasound and MRI (confirming absent uterus). AR gene sequencing. Androgen binding assay (fibroblasts).
10. TreatmentCAIS: gonadectomy (may be chosen after puberty; cancer risk about 2–3%), estrogen replacement, vaginal dilation/reconstruction if needed. PAIS: individualized treatment according to gender identity. Psychological support essential.
11. PrognosisCAIS: good social adjustment; good quality of life with estrogen replacement. Management of the risk of intragonadal germ cell tumors (gonadoblastoma/dysgerminoma) needed. Infertility.
12. PreventionGenetic counseling, prenatal testing for carrier women, early diagnosis and management in a multidisciplinary DSD clinic. Estrogen replacement and calcium and vitamin D supplementation to prevent osteoporosis.
13. ReferencesHughes IA et al. Androgen insensitivity syndrome (2012) and 9 others

1. History

First description of testicular feminization syndrome

The history of androgen resistance syndrome dates back to a 1953 paper published in the American Journal of Obstetrics and Gynecology by the American gynecologist John McLean Morris. Analyzing 82 cases, Morris first named a distinctive clinical syndrome with a 46,XY karyotype, completely female external genitalia, no uterus, and testes located intra-abdominally or in the inguinal region, using the term "testicular feminization syndrome". This description was an important finding suggesting that in sex development, not only the type of gonad but also the hormonal responsiveness of peripheral tissues is decisive.

However, at the time the pathophysiological mechanism was entirely unknown, and the description remained a simple phenotypic description of 'a feminized state despite the presence of testes'. In the 1960s, the discovery of an androgen-unresponsive mutant strain in a rat model (Tfm/Y mouse) made research on cellular androgen resistance possible. In the early 1970s, Keenan and colleagues first demonstrated, through in vitro studies using skin fibroblasts, that the dihydrotestosterone (DHT)-binding receptor protein is absent in patients with complete androgen insensitivity (1974). This proved at the molecular level that the cause of the syndrome is a defect in the androgen receptor (AR) itself.

Cloning of the androgen receptor gene and establishment of molecular classification

In 1988, Chang et al. and Lubahn et al. independently cloned the androgen receptor (AR) gene and determined its complete sequence (PMID: 3353717, PMID: 3353718), opening the era of molecular genetics of AIS. The AR gene was found to be located on the long arm of the X chromosome (Xq11-12) and to be a member of the nuclear receptor superfamily. Over the following decades, more than 1,000 pathogenic variants were identified throughout the AR gene, and the phenotypic spectrum according to variant type (complete loss vs partial impairment) and location (ligand-binding domain vs DNA-binding domain) was elucidated.

Clinical nomenclature was also revised during this period. As the term 'testicular feminization' was criticized for its stigmatizing effect, 'androgen insensitivity syndrome (AIS)' began to be adopted as the official term from 1994, subdivided according to phenotype into complete (CAIS), partial (PAIS), and mild (MAIS) forms. At the 2006 European–American consensus conference on disorders/differences of sex development (DSD), AIS was formally incorporated into the classification system as one of the representative causes of 46,XY DSD. In ICD-10 it is classified as E34.5 (androgen resistance syndrome), and in Korea it is a rare disease eligible for Special Copayment Reduction V166.


2. Causes

Androgen receptor gene variants

The cause of AIS is a pathogenic variant in the AR gene (androgen receptor gene, Xq11-12), with X-linked recessive inheritance. The AR gene consists of 8 exons and encodes the N-terminal transactivation domain (exon 1), the DNA-binding domain (exons 2–3), the hinge region (exon 4), and the ligand-binding domain (exons 5–8). Pathogenic variants are distributed across all these regions and occur in various forms, including point mutations (missense, nonsense), small insertions/deletions (frameshift), splice-site variants, and large deletions.

The effects of AR gene variants form a spectrum according to variant type. When no AR protein is produced or it is completely functionally inactivated, CAIS (complete form) occurs, and response to all androgens, including DHT, is lost. In contrast, variants with some remaining function (particularly partial impairment of the ligand-binding domain) result in PAIS (partial form), with intermediate impairment of virilization. With mild variants, the individual grows with a male phenotype, but MAIS (mild form) occurs, in which infertility or gynecomastia is the only finding. However, the genotype–phenotype correlation is not complete, and phenotypic diversity is observed even within families carrying the same variant.

Molecular mechanism: structure and function of the AR

The androgen receptor is a ligand-dependent transcription factor belonging to the nuclear receptor superfamily. Normally, the AR exists in an inactive state bound to a cytoplasmic heat shock protein (HSP90, HSP70) complex. When testosterone or its active form DHT binds, the AR dissociates from the heat shock proteins, moves to the nucleus, forms a dimer, and binds to androgen response elements (ARE) to activate transcription of target genes. If any step in this process is blocked by an AR variant, androgen signaling fails.

In addition to AR gene variants, abnormalities of AR cofactors (coactivator, corepressor), abnormal AR phosphorylation, and impaired DHT production due to 5α-reductase (SRD5A2) deficiency can also contribute to the androgen insensitivity phenotype. However, ICD-10 E34.5 currently refers mainly to the syndrome caused by variants in the AR gene itself, and SRD5A2 deficiency (5α-reductase deficiency) is classified separately (E29.1).


3. Genetics

X-linked recessive inheritance pattern

AIS is an X-linked recessive genetic disease, with the AR gene located on the long arm of the X chromosome (Xq11-12). Because 46,XY individuals have only one X chromosome, a single pathogenic variant in the AR gene is enough to cause the disease. 46,XX carrier women are phenotypically normal because the wild-type AR gene on the normal X chromosome compensates, but each son has a 50% chance of having AIS and each daughter a 50% chance of being a carrier. Meanwhile, about 30% of AIS patients are known to result from de novo mutations, so the disease occurs even without a family history.

Molecular structure of the AR gene and distribution of variants

The AR gene spans about 186 kb of the genome and consists of 8 exons. Exon 1 encodes the N-terminal domain (NTD), which accounts for about 50% of the entire coding sequence and contains the transactivation domain AF-1 and a serine–proline-rich region. In particular, exon 1 contains a CAG trinucleotide repeat, normally repeated 9–36 times. A reduced (short) CAG repeat number is associated with prostate cancer risk, and an increased repeat number (40 or more) causes Kennedy disease (spinal and bulbar muscular atrophy, SBMA). Exons 2–3 encode the two zinc finger structures of the DNA-binding domain (DBD), and variants in this region cause CAIS through inability to bind DNA. Exon 4 encodes the hinge region containing the nuclear localization signal (NLS), and exons 5–8 encode the ligand-binding domain (LBD), where most PAIS variants are concentrated.

More than 1,000 clinically significant AR variants have been registered to date in the international Androgen Receptor Gene Mutations Database, of which missense variants account for the largest proportion. The genotype–phenotype correlation is relatively predictable for LBD missense variants, but phenotypic diversity exists even with the same variant, and it is presumed that genetic background other than AR, epigenetic factors, and variants of AR coactivators are involved in modulating the phenotype.


4. General epidemiology

Incidence and prevalence

The incidence of complete androgen insensitivity syndrome (CAIS) is reported to be about 1/20,000–1/64,000 46,XY births, which is relatively common among diseases causing differences of sex development (DSD). The exact incidence of the partial form (PAIS) is difficult to determine because of the diversity of diagnostic criteria, and the mild form (MAIS) is often found incidentally during infertility workups, so the actual prevalence may be considerably underestimated. Some researchers estimate the incidence of all AIS, including MAIS, at more than 1/20,000 46,XY births.

No clear differences in incidence by race or ethnicity have been reported, but clustering of specific variants due to founder effects in certain populations has been reported. In Korea it is registered as a rare disease, and official counts of patients receiving Special Copayment Reduction V166 are limited, but the actual number of patients is presumed to be much higher than the number registered. This is because institutions operating DSD clinics are limited and it often takes time to reach a diagnosis.

Sex ratio and timing of diagnosis

AIS is a disease occurring in 46,XY individuals, but because CAIS patients grow up socially as women, they are recorded in medical records as 'female' patients. CAIS patients are most often first diagnosed with primary amenorrhea at puberty or with inguinal hernia in infancy to childhood. There are reports that about 1–2% of inguinal hernias in girls turn out to be CAIS, so clinical awareness of this diagnosis is important. PAIS is often first referred in the neonatal period for ambiguous genitalia, and MAIS is frequently diagnosed in male infertility clinics.


5. Pathophysiology

Normal process of fetal sex differentiation

Sex differentiation consists of three levels: genetic sex (karyotype), gonadal sex (testis or ovary), and phenotypic sex (internal and external genitalia). In a 46,XY fetus, when the SRY gene on the Y chromosome is expressed, the gonadal ridge differentiates into a testis; the Sertoli cells of the testis secrete anti-Müllerian hormone (AMH), causing regression of the Müllerian ducts that would become the uterus and fallopian tubes, and the Leydig cells secrete testosterone, forming the epididymis, vas deferens, and seminal vesicles from the Wolffian ducts. In the external genitalia, testosterone is converted to DHT by 5α-reductase (SRD5A2), inducing virilization such as formation of the penis and scrotum.

Disorders of sex development due to AR defects

In CAIS, AR function is completely lost, so even if testosterone and DHT are secreted at normal or elevated levels, no virilization occurs in target tissues (external genitalia, prostate anlage, etc.). AMH secretion by Sertoli cells occurs normally, so the uterus and fallopian tubes regress and are absent. As a result, the external genitalia are female (clitoris, labia, short blind-ending vagina), and the internal genitalia are neither male (Wolffian structures normal) nor female (no uterus) but absent. The testes are located intra-abdominally or in the inguinal region, and at puberty testosterone secreted by testicular Leydig cells is aromatized peripherally to estradiol, producing female secondary sex characteristics (breast development, female body fat distribution).

In PAIS, the AR functions partially, so virilization is partial, and various intermediate phenotypes such as hypospadias, clitoromegaly, and incomplete scrotal fusion appear. Penile size and shape, degree of scrotal fusion, and testicular position differ between individuals, and gender identity also varies widely. In MAIS, the male phenotype is complete, but owing to a slight decrease in AR function, gynecomastia and impaired spermatogenesis (azoospermia or oligospermia) appear at puberty or in adulthood.


6. Symptoms

Clinical symptoms of complete AIS (CAIS)

CAIS patients grow up with an outwardly completely female phenotype and live without particular symptoms until the condition is first suspected, mainly in two situations. First, when an inguinal hernia in infancy or childhood is found and testes are identified within the hernia sac during surgery. Because inguinal hernia is uncommon in girls, the possibility of AIS should always be kept in mind in this case. Second, when first diagnosed with primary amenorrhea after puberty. Breast development and a female body shape proceed normally under estradiol, but menarche does not occur because there is no uterus. In addition, markedly sparse or absent axillary and pubic hair is a characteristic finding.

Psychologically, CAIS patients have a strong female gender identity, and gender identity confusion is rare. However, on first learning of their DSD diagnosis, many experience psychological shock, depression, anxiety, and identity crises. The fact of infertility (inability to become pregnant) is also a psychological burden, so advance counseling and ongoing psychological support are important. The vagina may be short or absent, which can cause discomfort with or inability to have intercourse, and this can be improved by vaginal dilation or reconstruction.

Symptoms of partial AIS (PAIS) and mild AIS (MAIS)

PAIS patients are most often first referred in the neonatal period for ambiguous genitalia. Micropenis, hypospadias, bifid scrotum, incomplete scrotal fusion, and the like appear in various combinations. At puberty, sexual development may proceed in an unexpected direction (e.g., a tendency toward feminization or undervirilization), and psychological difficulties are considerable. In MAIS, the male phenotype is complete, but after puberty gynecomastia, impaired spermatogenesis, infertility, micropenis, and the like may appear as the only symptoms. There are cases in which an AR variant is found while performing genetic testing for the cause of azoospermia or oligospermia in a male infertility clinic.


7. Signs

Physical and biochemical findings

Physical examination findings of CAIS include female external genitalia (normal clitoris, no clitoromegaly), a blind-ending vagina (1–7 cm in length, with wide individual variation), markedly sparse axillary and pubic hair, and testes located in the pelvis or inguinal region (palpable or confirmed by imaging). Patients tend to be taller than average women with a somewhat masculine skeleton, which is understood as an effect of height-related genes on the Y chromosome. Pelvic ultrasound or MRI shows no uterus or ovaries and confirms the location of the testes.

Biochemical findings are characterized by serum testosterone elevated to the normal or upper level for adult men (because there is no androgen action, negative feedback is insufficient, so LH increases and LH-driven testosterone stimulation persists), markedly elevated LH, normal or slightly elevated FSH, estradiol at normal female levels (due to peripheral aromatization), and AMH elevated to normal male levels. Serum androstenedione and DHEAS can also be measured, and adrenal function is normal. Serum SHBG varies, reflecting the estradiol/androgen ratio.

Karyotype and molecular findings

The karyotype of patients with CAIS is 46,XY, and this is one of the most essential diagnostic clues. It is confirmed by G-banding karyotype analysis, and if necessary the Y chromosome can be confirmed using FISH (fluorescence in situ hybridization) or a SNP array. Sequencing of the AR gene identifies a pathogenic variant. In androgen-binding assays using immunohistochemistry or fibroblasts, binding activity is markedly reduced or absent. Pathologic findings of the gonadal tissue show testicular architecture (seminiferous tubules, Leydig cells), spermatogenesis is markedly reduced or absent, and after puberty there is a risk of intragonadal germ cell tumors (mainly gonadoblastoma or dysgerminoma).


8. Screening

Initial screening in situations of clinical suspicion

Population screening for AIS is not performed. However, immediate screening is recommended in specific clinical situations. First, inguinal hernia in girls: during inguinal hernia surgery in girls, examination of the hernia sac contents and biopsy of suspicious tissue, followed by karyotype analysis, are recommended. Second, primary amenorrhea at puberty: when amenorrhea is present with breast development (i.e., female secondary sexual characteristics are present but the uterus is absent), karyotype analysis is essential to differentiate from Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome. Third, ambiguous sex determination in the newborn (DSD): a DSD panel including AR gene testing is performed within the 46,XY DSD evaluation protocol.

Family history-based screening

Prenatal genetic testing (AR gene analysis by chorionic villus sampling or amniocentesis) is possible for XY fetuses of female carriers (mother, maternal aunt, maternal grandmother, etc.) of patients with CAIS or PAIS. Because 50% of the daughters of a female carrier become carriers, prenatal diagnosis may also be requested for female fetuses to determine carrier status. However, prenatal diagnosis should be applied only after thorough discussion through genetic counseling and with respect for patient autonomy.


9. Diagnosis

Hormonal and genetic testing

The diagnosis of AIS is made by integrating clinical findings, hormone testing, karyotype analysis, and AR gene testing. Hormone profile: in CAIS, serum testosterone at or above the upper limit of the normal adult male range, markedly elevated LH, normal to mildly elevated FSH, estradiol in the normal female range, and elevated AMH (male level). In prepubertal children, an hCG stimulation test is performed to confirm testicular function (testosterone response). The DHT/testosterone ratio can be used to differentiate from 5α-reductase deficiency.

Karyotype analysis: G-banding karyotype analysis of peripheral blood lymphocytes confirms 46,XY. Detailed analysis using FISH or SNP microarray excludes additional abnormalities such as Y chromosome microdeletions. AR gene sequencing: Sanger sequencing of all of exons 1–8 or a next-generation sequencing (NGS) panel is performed to identify pathogenic variants. If no variant is found, AR mRNA expression analysis using RT-PCR and screening for large deletions using MLPA (multiplex ligation-dependent probe amplification) may be added.

Imaging and tissue examination

Pelvic ultrasound and MRI are important for confirming the absence of the uterus and ovaries and the location of the testes. MRI has better soft-tissue resolution than ultrasound and is advantageous for determining the location of intra-abdominal testes and their relationship to surrounding structures. Histopathologic examination of resected gonadal tissue confirms testicular tissue architecture and evaluates for the presence of germ cell tumors (intratubular germ cell neoplasia, ITGCN; gonadoblastoma, etc.). The immunohistochemical markers OCT3/4, PLAP, and c-KIT (CD117) are used in the diagnosis of germ cell tumors.


10. Treatment

Gonadal management: timing and method of gonadectomy

In patients with CAIS, testes located in the abdomen or inguinal region carry a risk of malignant transformation (gonadoblastoma, dysgerminoma). The risk of gonadal malignancy in CAIS is relatively low at about 2–3% and is known to occur mainly after adulthood. Therefore, whereas gonadectomy was previously recommended immediately upon diagnosis, recent guidelines have shifted toward retaining the gonads in CAIS until after puberty (after estrogen production is complete and psychological maturity has been reached) and deciding whether and when to perform gonadectomy with the patient's full understanding and consent. Gonadectomy is performed laparoscopically and can be done at the same time as inguinal hernia repair or as a separate operation. The resected testes must always undergo histopathologic examination.

In PAIS, the timing and approach of gonadectomy differ according to the sex of rearing (sex assignment). If raised as female, management is similar to CAIS; if raised as male, the gonads are preserved but regular tumor surveillance is performed.

Hormone replacement and vaginoplasty

After gonadectomy or in gonadal failure, estrogen replacement therapy (HRT) is started to prevent osteoporosis, maintain cardiovascular health, prevent vulvar atrophy, and improve quality of life. Various formulations are used, including oral 17β-estradiol (1–2 mg/day), transdermal estradiol patches, and gels. Even when the gonads remain, estradiol acts as the main sex hormone because there is no androgen action.

When the vagina is short or absent, non-surgical vaginal dilation therapy (the Frank method or use of other dilators) is recommended as first-line treatment, with a high success rate and few adverse effects. Surgical vaginoplasty (e.g., McIndoe procedure, Vecchietti procedure) is considered only when non-surgical methods do not achieve sufficient results. To prevent osteoporosis, calcium and vitamin D supplementation and bone density DXA scans are performed regularly.

Psychological support and multidisciplinary approach

Patients with AIS face psychological challenges at several stages, including diagnosis, the fact of infertility, surgical decisions, and hormone therapy. Psychological support and psychiatric consultation should be integrated from the start of treatment, and connecting patients with support groups (peer support group) is also helpful. A multidisciplinary DSD clinic system consisting of endocrinology, pediatrics, urology, gynecology, medical genetics, psychology, and ethics specialists ensures the best treatment outcomes. The timing and method of disclosure of diagnostic information are carefully planned, taking into account age, developmental level, and family circumstances.


11. Prognosis

Long-term prognosis and quality of life

Patients with CAIS who receive appropriate hormone replacement and psychological support generally adapt well socially and occupationally and maintain their lives as women. Gender identity is stably female, and the frequency of gender dysphoria is reported to be similar to or lower than that of the general population. Quality-of-life studies have confirmed that factors such as disclosure of the diagnosis, infertility, surgical experience, and hormone therapy affect quality of life, and that appropriate medical support and psychological counseling contribute to improving quality of life.

The risk of gonadal malignancy (about 2–3%) is managed by gonadectomy or ongoing tumor surveillance, and because discontinuing estrogen replacement can lead to osteoporosis, vasomotor symptoms, and urogenital atrophy, continuation of estrogen replacement until the age of menopause is recommended. Biological infertility is irreversible, but the experience of motherhood is possible through non-traditional means (e.g., surrogacy, adoption).

Prognosis of PAIS and MAIS

The prognosis of patients with PAIS depends greatly on sex assignment, the results of reconstructive surgery, psychological support, and the development of the patient's own gender identity. Recent international guidelines are moving toward delaying sex assignment and related surgery as long as possible so that the patient's own gender identity can be fully expressed. In MAIS, the core of treatment is fertility counseling, correction of gynecomastia (if desired), and psychological support, and the overall prognosis is good.


12. Prevention

Primary prevention: genetic counseling and prenatal diagnosis

There is currently no way to prevent AIS itself. However, in families that already have a patient with AIS, female carriers can be identified through genetic counseling, and if desired, prenatal genetic testing (AR gene analysis by chorionic villus sampling or amniocentesis) can be performed to prepare for the next pregnancy. Preimplantation genetic testing (PGT) is also technically possible. Genetic counseling should be conducted in a non-directive manner, including the psychological impact of test results, the right to autonomous decision-making, and the limitations of testing.

Secondary prevention: early diagnosis and prevention of complications

Secondary prevention of AIS focuses on preventing complications (osteoporosis, gonadal tumors, psychological problems) through early diagnosis. Karyotyping is performed promptly in girls with inguinal hernia, and AIS is always included in the differential diagnosis of patients with primary amenorrhea. After diagnosis, early referral to psychological counseling, initiation of estrogen replacement (after gonadectomy), regular bone density measurement, and gonadal tumor surveillance are carried out systematically. A disclosure plan is established with the multidisciplinary team, tailored to the patient's age and psychological state.

Tertiary prevention: long-term management and follow-up

The adequacy of estrogen replacement therapy is evaluated regularly, and bone density (DXA) is measured every 2–3 years to take measures to prevent osteoporosis. If gonadectomy has not been performed, pelvic MRI and AFP and β-hCG (tumor markers) are measured regularly (every 6 months to 1 year) to monitor for gonadal tumors. Social isolation and depression are prevented through connection to patient support groups and ongoing psychological support. A system of regular follow-up with the relevant specialized DSD clinic is maintained.


13. References

  1. Hughes IA, Davies JD, Bunch TI, Pasterski V, Mastroyannopoulou K, MacDougall J. Androgen insensitivity syndrome. Lancet. 2012;380(9851):1419–1428. PMID: 22901741
  2. Quigley CA, De Bellis A, Marschke KB, El-Awady MK, Wilson EM, French FS. Androgen receptor defects: historical, clinical and molecular perspectives. Endocr Rev. 1995;16(3):271–321. PMID: 7671849
  3. Gottlieb B, Beitel LK, Nadarajah A, Paliouras M, Trifiro M. The androgen receptor gene mutations database: 2012 update. Hum Mutat. 2012;33(5):887–894. PMID: 22334387
  4. Ahmed SF, Achermann JC, Arlt W, et al. UK guidance on the initial evaluation of an infant or an adolescent with a suspected disorder of sex development. Clin Endocrinol (Oxf). 2011;75(1):12–26. PMID: 21521319
  5. Hannema SE, Scott IS, Hodapp J, et al. Residual activity of mutant androgen receptors explains wolffian duct development in the complete androgen insensitivity syndrome. J Clin Endocrinol Metab. 2004;89(11):5815–5822. PMID: 15531549
  6. Cheikhelard A, Morel Y, Thibaud E, et al. Long-term followup and comparison between genotype and phenotype in 29 cases of complete androgen insensitivity syndrome. J Urol. 2008;180(4):1496–1501. PMID: 18710721
  7. Deans R, Creighton SM, Liao LM, Conway GS. Timing of gonadectomy in adult women with complete androgen insensitivity syndrome (CAIS): patient preferences and clinical evidence. Clin Endocrinol (Oxf). 2012;76(6):894–898. PMID: 22220997
  8. Bouvattier C, Mignot B, Lefèvre H, Morel Y, Bougnères P. Impaired sexual activity in male adults with partial androgen insensitivity. J Clin Endocrinol Metab. 2006;91(9):3310–3315. PMID: 16757522
  9. Hiort O, Birnbaum W, Marshall L, et al. Management of disorders of sex development. Nat Rev Endocrinol. 2014;10(9):520–529. PMID: 24889177
  10. Batista RL, Costa EMF, Rodrigues AS, et al. Androgen insensitivity syndrome: a review. Arch Endocrinol Metab. 2018;62(2):227–235. PMID: 29768638